Form 4: Royalty Pharma EVP Marshall Urist Reports Acquisition of Shares Through Equity Performance Award Settlement

Marshall Urist, EVP of Research & Investments at Royalty Pharma plc, reports acquiring 36,484 Class A Ordinary Shares through the settlement of Equity Performance Awards.

Summary

• On May 8, 2025, Marshall Urist, EVP of Research & Investments at Royalty Pharma plc, acquired 36,484 Class A Ordinary Shares.
• This acquisition was due to the settlement of Equity Performance Awards, as per Rule 16b-3.
• The shares were acquired at a price of $0.
• Following the transaction, Urist directly owns 83,151 Class A Ordinary Shares.
• Urist also indirectly owns 19,020 Class A Ordinary Shares through an IRA.

Sentiment

Score: 6

Explanation: The sentiment is neutral as it's a standard reporting of stock acquisition through equity awards. It doesn't inherently indicate positive or negative performance.

Positives

• The acquisition of shares by a company executive can be seen as a positive sign, indicating confidence in the company's future performance.

Industry Context

This filing is a routine disclosure related to executive compensation and stock ownership, common in publicly traded companies.

Stakeholder Impact

• The transaction may have a minor positive impact on shareholder sentiment, as it indicates an executive's increased stake in the company.

Key Dates

Keywords

Royalty Pharma, Marshall Urist, Equity Performance Awards, Class A Ordinary Shares, Beneficial Ownership, Form 4, SEC, RPRX